Cargando…

A CCHFV DNA vaccine protects against heterologous challenge and establishes GP38 as immunorelevant in mice

Crimean-Congo hemorrhagic fever virus (CCHFV) is a tick-borne virus that causes severe hemorrhagic fever disease in humans. Currently, no licensed CCHF vaccines exist, and the protective epitopes remain unclear. Previously, we tested a DNA vaccine expressing the M-segment glycoprotein precursor gene...

Descripción completa

Detalles Bibliográficos
Autores principales: Suschak, John J., Golden, Joseph W., Fitzpatrick, Collin J., Shoemaker, Charles J., Badger, Catherine V., Schmaljohn, Connie S., Garrison, Aura R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7925670/
https://www.ncbi.nlm.nih.gov/pubmed/33654101
http://dx.doi.org/10.1038/s41541-021-00293-9
_version_ 1783659320550883328
author Suschak, John J.
Golden, Joseph W.
Fitzpatrick, Collin J.
Shoemaker, Charles J.
Badger, Catherine V.
Schmaljohn, Connie S.
Garrison, Aura R.
author_facet Suschak, John J.
Golden, Joseph W.
Fitzpatrick, Collin J.
Shoemaker, Charles J.
Badger, Catherine V.
Schmaljohn, Connie S.
Garrison, Aura R.
author_sort Suschak, John J.
collection PubMed
description Crimean-Congo hemorrhagic fever virus (CCHFV) is a tick-borne virus that causes severe hemorrhagic fever disease in humans. Currently, no licensed CCHF vaccines exist, and the protective epitopes remain unclear. Previously, we tested a DNA vaccine expressing the M-segment glycoprotein precursor gene of the laboratory CCHFV strain IbAr 10200 (CCHFV-M(10200)). CCHFV-M(10200) provided >60% protection against homologous CCHFV-IbAr 10200 challenge in mice. Here, we report that increasing the dose of CCHFV-M(10200) provides complete protection from homologous CCHFV challenge in mice, and significant (80%) protection from challenge with the clinically relevant heterologous strain CCHFV-Afg09-2990. We also report complete protection from CCHFV-Afg09-2990 challenge following vaccination with a CCHFV-Afg09-2990 M-segment DNA vaccine (CCHFV-M(Afg09)). Finally, we show that the non-structural M-segment protein, GP38, influences CCHF vaccine immunogenicity and provides significant protection from homologous CCHFV challenge. Our results demonstrate that M-segment DNA vaccines elicit protective CCHF immunity and further illustrate the immunorelevance of GP38.
format Online
Article
Text
id pubmed-7925670
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-79256702021-03-19 A CCHFV DNA vaccine protects against heterologous challenge and establishes GP38 as immunorelevant in mice Suschak, John J. Golden, Joseph W. Fitzpatrick, Collin J. Shoemaker, Charles J. Badger, Catherine V. Schmaljohn, Connie S. Garrison, Aura R. NPJ Vaccines Article Crimean-Congo hemorrhagic fever virus (CCHFV) is a tick-borne virus that causes severe hemorrhagic fever disease in humans. Currently, no licensed CCHF vaccines exist, and the protective epitopes remain unclear. Previously, we tested a DNA vaccine expressing the M-segment glycoprotein precursor gene of the laboratory CCHFV strain IbAr 10200 (CCHFV-M(10200)). CCHFV-M(10200) provided >60% protection against homologous CCHFV-IbAr 10200 challenge in mice. Here, we report that increasing the dose of CCHFV-M(10200) provides complete protection from homologous CCHFV challenge in mice, and significant (80%) protection from challenge with the clinically relevant heterologous strain CCHFV-Afg09-2990. We also report complete protection from CCHFV-Afg09-2990 challenge following vaccination with a CCHFV-Afg09-2990 M-segment DNA vaccine (CCHFV-M(Afg09)). Finally, we show that the non-structural M-segment protein, GP38, influences CCHF vaccine immunogenicity and provides significant protection from homologous CCHFV challenge. Our results demonstrate that M-segment DNA vaccines elicit protective CCHF immunity and further illustrate the immunorelevance of GP38. Nature Publishing Group UK 2021-03-02 /pmc/articles/PMC7925670/ /pubmed/33654101 http://dx.doi.org/10.1038/s41541-021-00293-9 Text en © This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Suschak, John J.
Golden, Joseph W.
Fitzpatrick, Collin J.
Shoemaker, Charles J.
Badger, Catherine V.
Schmaljohn, Connie S.
Garrison, Aura R.
A CCHFV DNA vaccine protects against heterologous challenge and establishes GP38 as immunorelevant in mice
title A CCHFV DNA vaccine protects against heterologous challenge and establishes GP38 as immunorelevant in mice
title_full A CCHFV DNA vaccine protects against heterologous challenge and establishes GP38 as immunorelevant in mice
title_fullStr A CCHFV DNA vaccine protects against heterologous challenge and establishes GP38 as immunorelevant in mice
title_full_unstemmed A CCHFV DNA vaccine protects against heterologous challenge and establishes GP38 as immunorelevant in mice
title_short A CCHFV DNA vaccine protects against heterologous challenge and establishes GP38 as immunorelevant in mice
title_sort cchfv dna vaccine protects against heterologous challenge and establishes gp38 as immunorelevant in mice
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7925670/
https://www.ncbi.nlm.nih.gov/pubmed/33654101
http://dx.doi.org/10.1038/s41541-021-00293-9
work_keys_str_mv AT suschakjohnj acchfvdnavaccineprotectsagainstheterologouschallengeandestablishesgp38asimmunorelevantinmice
AT goldenjosephw acchfvdnavaccineprotectsagainstheterologouschallengeandestablishesgp38asimmunorelevantinmice
AT fitzpatrickcollinj acchfvdnavaccineprotectsagainstheterologouschallengeandestablishesgp38asimmunorelevantinmice
AT shoemakercharlesj acchfvdnavaccineprotectsagainstheterologouschallengeandestablishesgp38asimmunorelevantinmice
AT badgercatherinev acchfvdnavaccineprotectsagainstheterologouschallengeandestablishesgp38asimmunorelevantinmice
AT schmaljohnconnies acchfvdnavaccineprotectsagainstheterologouschallengeandestablishesgp38asimmunorelevantinmice
AT garrisonaurar acchfvdnavaccineprotectsagainstheterologouschallengeandestablishesgp38asimmunorelevantinmice
AT suschakjohnj cchfvdnavaccineprotectsagainstheterologouschallengeandestablishesgp38asimmunorelevantinmice
AT goldenjosephw cchfvdnavaccineprotectsagainstheterologouschallengeandestablishesgp38asimmunorelevantinmice
AT fitzpatrickcollinj cchfvdnavaccineprotectsagainstheterologouschallengeandestablishesgp38asimmunorelevantinmice
AT shoemakercharlesj cchfvdnavaccineprotectsagainstheterologouschallengeandestablishesgp38asimmunorelevantinmice
AT badgercatherinev cchfvdnavaccineprotectsagainstheterologouschallengeandestablishesgp38asimmunorelevantinmice
AT schmaljohnconnies cchfvdnavaccineprotectsagainstheterologouschallengeandestablishesgp38asimmunorelevantinmice
AT garrisonaurar cchfvdnavaccineprotectsagainstheterologouschallengeandestablishesgp38asimmunorelevantinmice